1. Foster H, Hooper M, Imann S H, Lovett G S, Nicholson J, Swain C J, Sweetman A J, Weetman
D F. (1983) Biological Activities of Isatogens Brit. J. Pharm., 79, 273.
2. Baker R, Bhaskar Rao V, Ravenscroft P D, Swain C J.(1983) Oxidation of Trimethylsilyl ethers.
Synthesis, 572 (1983).
3. Baker R, Bayes R H O, Broom D M P, Devlin J A, Swain C J. (1983) The Chemistry of
Spiroacetals: Enantiospecific synthesis of the spiroacetal unit of Milbemycin b3.
J. Chem. Soc. Chem. Commun, 829.
4. Baker R, Ravenscroft P D, Swain C J. (1984) The total synthesis of Ancistrofuran. J. Chem. Soc.
Chem. Commun. 74.
5. Baker R, Gibson C L, Swain C J., Tapolsczay D J. (1984) Synthetic studies on Paniculides.
J. Chem. Soc. Chem. Commun. 619.
6. Baker R, O’Mahony M J, Swain C J. (1984) The total synthesis of Wintermoth Pheromone. J.
Chem. Res. 190.
7. Baker R, Head J C, Swain C J. (1985) The Chemistry of Spiroacetals: Enantiospecific Synthesis
of the spiroacetal unit of Avermectin b1b and b2b. J. Chem. Soc. Chem. Commun. 309.
8. Baker R, Swain C J, Head J. (1985) Recent Advances in the Chemistry of Insect Control.
Ed. N.F. Jones, Pub. The Royal Society of Chemistry. p.245.
9. Baker R, Gibson C L, Swain C J, Tapolczay D J. (1985) Synthetic studies on the Paniculides.
J. Chem Soc. Perk I, 1590.
10. Baker R, Cotterell I F, Ravenscroft P D, Swain C J. (1985) The total synthesis of Ancistrofuran.
J. Chem. Soc. Perk I, 2463.
11. Baker R, O’Mahony M J, Swain C J. (1985) The total synthesis of (+) Milbemycin β3.
J. Chem. Soc. Chem. Commun., 1326.
12. Baker R, Head J C, Swain C J. (1985) Chemistry of Spiroacetals, Enantiospecific synthesis of the
spiroacetal units of milbemycins a7 and a8. J. Chem. Soc. Chem. Commun., 874.
13. Hooper M, Adams D B, Swain C J, Raper E S, Stoddart B. (1986) Isatogens: X-ray crystal
structure. J. Chem. Soc. Perk. I, 1005.
14. Swain C J, Baker R, O’Mahony. (1986) A formal synthesis of Milbemycin b3.
Tetrahedron Lett. 27, 3059.
15. Baker R, Boyes R H O, Broom D M P, O’Mahony M J, Swain C J. (1987) Enantiospecific
synthesis of the spiroacetal unit of Milbemycin b3. J. Chem. Soc. Perkin Trans 1, 1613.
16. Baker R, O’Mahony M J, Swain C J. (1987) The total synthesis of (+) Milbemycin b3.
J. Chem. Soc. Perkin Trans. 1, 1623.
17. Baker R, Head J C, Swain C J. (1988) Synthesis of spiroacetals.
J. Chem. Soc. Perkin Trans 1., 85.
18. Castro J L, Baker R, Swain C J. (1988) Directed Aldol Chemistry.
Tet. Lett. 29 (18) 2247.
19. Watling K J, Aspley S, Swain C J, Saunders J. (1988) Radioligand binding assay for 5-HT3
antagonists. Eur. J. Pharmac. 149, 397.
20. Baker R, Boyes A L, Swain C J. (1989) The total synthesis of Talaromycins A,B,C and E.
Tet. Lett, 30 (8) 985.
21. Baker R, Swain C J. Ivermectin – A drug for all seasons. Chem. in Brit., 692.
22. Watgen F, Baker R, Engelstoff M, Herbert R, MacLeod A, Knight A, Merchant K, Moseley
J, Saunders J, Swain C J. Wong E, Springer J P. (1989) Novel Benzodiazepine Receptor Partial
Agonists: Oxadiazolylimidazobenzodiazepines. J. Med. Chem.. 32, 2282.
23. Swain C J, Kneen C, Baker R. (1990) Synthesis of Indole Oxazolines, Potent 5-HT3 antagonists.
Tet. Lett. 31, 2445.
24. Baker R, Boyes A L, Swain C J. (1990) Synthesis of Talaromycins A, B, C and E.
J. Chem. Soc. Perkin Trans 1., 1415.
25. McKernan R M, Gillard N P, Quirk K, Kneen C O, Stevenson G I, Swain C J, Ragan C I.
(1990) Purification of the 5-HT3 receptor from NCB20 cells. J. Biol. Chem. 265 (23), 13572.
26. Swain C J, Kneen C, Herbert R, Baker R. (1990) Synthesis of Indole Oxazolines: Novel 5-HT3
antagonists. J. Chem. Soc. Perkin Trans 1 3183.
27. Swain C J, Baker R, Kneen C, Moseley J, Saunders J, Seward E M, Stevenson G, Beer M,
Stanton J, Watling K. (1991) Novel 5-HT3 Antagonists. Indole Oxadiazoles.
J. Med. Chem. 34, 140.
28. Booth S E, Jenkins P R, Swain C J. (1991) The Synthesis of Bicyclic and Tricyclic Ring Systems
by Radical Cyclisation Reactions of Oxime ethers. J. Chem Soc. Chem. Commun. 1248.
29. Tattersall D, Newberry N, Beer M, Rigby M, Gilbert M, Maquire J, Mudunotuwa N,
Duchonowski M, McKnight A, Swain C J, Kneen C, Dourish C. (1992)
L-683,877: Pharmacological Profile of a Novel 5-HT3 Receptor Antagonist.
Drug Development Research, 25, 25, 17.
30. Swain C J, Baker R, Kneen C, Herbert R, Moseley J, Saunders J, Seward E M, Stevenson G I,
Beer M, Stanton J, Watling K, Ball R G. (1992) Novel 5-HT3 Antagonists: Indol-3
-ylspiro(azabicycloalkane-3,51(41H)-oxazoles). J Med. Chem., 35, 1019.
31. Cascieri M A, Ber E, Tung M F, Sadowski S, Bansal S, Swain C J, Seward E M, Frances B,
Burns D, Strader C D. (1992) Characterization of the binding of a potent, selective,
radioiodinated antagonist to the human neurokinin-1 receptor. Molecular Pharmacology, 42, 458
-463.
32. Jenkins P, Symons M C R, Booth S E, Swain C J. (1992) Why is a vinyl anion configurationally
stable but a vinyl radical configurationally unstable. Tet. Lett., 33, 3543.
33. Rajagopal S, Diksic M, Francis B, Swain C J, Burns H D. (1992) Synthesis of a 11C-labeled
novel, quinuclidine based ligand for the 5-HT3 receptor. Applied Radiation and Isotopes, 43,
1369-1373,
34. Francis B E, Swain C J, Sabin V, Burns H D. Radioiodinated L-703,606:A Potent Selective
Antagonist to the human NK1 Receptor. Appl. Radiat. Isot.
35. Booth S E, Jenkins P R, Swain C J. (1993) A novel Ring expansion reaction in the reduction of
Benzylic Methoxyamines with Lithium Aluminium Hydride. J. Chem. Soc. Chem. Commun.,
147.
36. Cascieri M A, Fong T M, Yu H, Bansai A, Swain C J, Strader C D. (1993). Amino-aromatic
interaction between histidine 197 of the NK1 receptor and CP 96345. Nature, 362, 350.
37. Seward E M, Swain C J, Merchant K J, Owen S N, Savin V, Cascieri M A, Sadowski S, Strader
C D, Baker R. (1993) Quinuclidine Based NK1 antagonists 1: 3-Benzyloxy-1-azabicyclo[2.2.2]
octanes. Bioorganic and Med. Chem. Lett., 3, (6), 1361.
38. MacLeod A M, Merchant K J, Cascieri M A, Shadowski S, Ber E, Swain C J, Baker R. (1993)
N-Acyl-L-Tryptophan Benzyl Esters: Potent Substance P antagonists. J. Med. Chem. 36, 2044.
39. Swain C J, Seward E M, Sabin V, Owen S, Baker R, Cascieri M A, Sadowski S, Strader C,
Ball R G. (1993) Quinuclidine Based NK1 Antagonists 2: Determination of the Absolute
Stereochemical Requirements, Bioorganic and Med. Chem. Lett. 3 (8), 1703.
40. Fong T M, Yu H, Cascieri M A, Underwood D, Swain C J, Strader C D. (1994) The role of the
Histidine 265 in Antagonist Binding to the NK1 Receptor. J. Biol. Chem. 269 (4), 2728.
41. Cascieri M A, MacLeod A M, Underwood D, Shiao L, Ber E, Sadowski S, Yu H, Merchant K
J, Swain C J, Strader C D, Fong T M. (1994) Characterization of the Interaction of N-Acyl-L
-Tryptophan Benzyl Ester Neurokinin Antagonists with the human NK1 receptor. J. Biol. Chem.
269 (9), 6587.
42. MacLeod A M, Merchant K J, Brookfield F, Kelleher F, Stevenson G, Owens A P, Swain C J,
Cascieri M A, Sadowski S, Ber E, Strader C D, Macintyre D E, Metzger J M, Ball R G, Baker
R. (1994) Identification of L-Tryptophan Derivatives with Potent and Selective Activity at the
NK1 receptor. J. Med. Chem. 37, 1269.
43. Fong T M, Yu H, Cascieri M A, Underwood D, Swain C J, Strader C D. (1994) Interaction of
Glutamine 165 in the fourth Transmembrane Segment of the human NK1 Receptor with
Quinuclidine Receptor with Quinuclidine Antagonists. J. Biol. Chem. 269 (21) 14957.
44. Williams B J, Teall M, McKenna J, Harrison T, Swain C J, Cascieri M A, Sadowski S, Strader C
D, Baker R. (1994) Acyclic NK1 Antagonists: 2-Benzhydryl-2-aminoethyl ethers. Bioorg. and
Med. Chem. Lett. 4, (16), 1903.
45. Swain C J, Cascieri M A, Owens A, Saari W, Sadowski S, Strader C, Teall M, Van Niel M B,
Williams B J. (1994) Acyclic NK1 antagonists: Replacement for the benzhydryl group.
Bioorganic and Med. Chem. Lett. 4, (18), 2161.
46. Harrison T, Williams B J, Swain C J, Ball R G. (1994) Piperidine-Ether Based hNK1
Antagonists 1: Determination of the Relative and Absolute Stereochemical Requirements.
Bioorganic and Med. Chem. Lett. 4 (21), 2545.
47. Harrison T, Williams B J, Swain C J. (1994) Gem-Disubstituted Amino-ether Based Substance P
antagonists. Bioorganic and Med. Chem. Lett. 4 (23), 2733.
48. Jenkins P R, Booth S E, Swain C J, Sweeny J B. (1994) Intramolecular Addition of Vinyl and
Aryl radicals to Oxime ethers in the synthesis of Five, Six and Seven-membered Ring Systems.
J. Chem. Soc. Perkin Trans. 1. 3499.
49. Longmore J, Swain C J, Hill R G. (1995) Neurokinin Receptors. Drug News and Perspectives.
8 (1), 5.
50. Cascieri M A, Shiao L, Mills S G, MacCoss M, Swain C J, Yu H, Ber E, Sadowski S, Wu M T,
Strader C D, Fong T M. (1995) Characterisation of the Interaction of Diacylpiperazine
Antagonists with the human NK1 receptor: Identification of a Common Binding site for
structurally Dissimilar Antagonists. Mol. Pharm. 47, 660.
51. Swain C J., Fong T M, Haworth K, Owen S N, Seward E M. (1995) Quinuclidine based NK1
antagonists the role of the benzhydryl. Biorganic and Med. Chem. Lett. 5(12), 1261.
52. Fong T M, Ruey-Ruey C, Huang H Y, Swain C J, Underwood D, Cascieri M A, Strader C D.
(1995) Mutational analysis of neurokinin receptor function. Cam. J. Physiol. Pharmacol. 73,
860.
53. Owens A P, Williams B J, Harrison T, Swain C J, Baker R, Sadowski S, Cascieri M A. (1995)
Phenyl-Glycinol Based NK1 receptor antagonists-Towards the minimum Pharmacophore,
Biooganic and Med. Chem. Lett. 5 (22), 2761.
54. Swain C J, Seward E M, Cascieri M A, Fong T M, Herbert R, MacIntyre D E, Merchant K J,
Owen S, Owens A P, Sabin V, Teall M, Van Niel M B, Williams B J, Sadowski S, Strader C D,
Ball R G, Baker R. (1995) Identification of a series of 3-Benzyloxy-l-azabicyclo[2.2.2]octane
human NK1 antagonists. J. Med. Chem. 38, 4793 .
55. Fong T M, Yu H, Huang R-R, , Swain C J, Undewrwood D, Cascieri M A, Strader C D, (1995)
Mutational analysis of neurokinin receptor function, Can. J. Physiol. Pharmacol. 73, 860
56. Swain C J, (1996) Neurokinin Receptor Antagonists, Expert Opinion on Theraputic Patents, 6 (4)
367.
57. Swain C J, (1996) Neurokinin Receptor Antagonists, Drug Discovery Today, 1 (6)
58. Ladduwahetty T, Swain C J, Keown L, Seward E M, Haworth K, Owen S, Chambers M, Baker
R, Cascieri M A, Hargreaves R J, Iversen L L, MacIntyre D E, Metzger J M, Sadowski S,
Shepheard S, Strader C D, Tattersal F D, (1996) L-741,671: A potent orally active human NK1
antagonist, J. Med. Chem. 39, 2907
59. Swain C J, Hargreaves R,J (1996) Neurokin Receptor Antagonists, Annual Reports in Medicinal
Chemistry, 31, Chapter 12, 111
60. Fong T M, Yu H, Huang R-R, Cascieri M A, Swain C J, (1996) Relative Contribution of Polar
Interactions and Conformational Compatibility to the binding of Neurokinin-1 Receptor
Antagonists, Molecular Pharmacology, 50, 1605
61. Tattersall F D, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod A M, Ladduwahetty T,
Keone L, Swain C, Baker R, Cascieri M, Ber E, Metzger J, MacIntyre D E, Hill R, Hargreaves R,
(1996) Tachykinin NK1 Receptor Antagonists act centrally to inhibit Emesis Induced by the
chemotheraputic agent Cisplatin in FerretsNeuropharmacolgy, 35, 8, 1121.
62. Rupniak N M J, Tattersall F D, Williams A R, Rycroft W, Carlson E J, Cascieri M, Sadowski S,
Ber E, Hale J, Mills S, MacCoss M, Seward E, Huscroft I, Owen S, Swain C J, Hill R G,
Hargreaves R J, (1997) In vitro and in vivo predictors of the anti-emetic activity of tachykinin
NK1 receptor antagonists, Eur J Pharmacol. 326, 201.
63. Swain C J, Williams B J, Baker R, Cascieri M A 1, Chicchi G 1, Forrest M 2, Herbert R, Keown
L, Ladduwahetty T, Luell S, MacIntyre D E, Metzger J, Morton S, Owens A P, Sadowski S 1 and
Watt A P. (1997) 3-Benzyloxy-2-Phenylpiperidine NK1 antagonists: The influence of alpha
methyl substitution. Bioorganic and Medchem Letters, 7 (23), 2959.
64. Owens A P, Harrison T, Moseley J D, Swain C J, Sadowski S 1 and Cascieri M A. (1998) High
Affinity Phenylglycinol-Based NK1 Antagonists. Bioorganic and Medchem Letters, 8 (1), 51.
65. Kramer M S, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek J J, Reines S A, Liu G,
Snavely D, Wyatt-Knowles E, Hale J J, Mills S G, MacCoss M, Swain C J, Harrison T, Hill R G,
Hefti F, Scolnick E M, Cascieri M A, Chicchi G G, Sadowski S, Williams A R, Hewson L, Smith
D, Carlson E J, Hargreaves R J and Rupniak N M J, (1998) Distinct Mechanism for
Antidepressant Activity by Blockade of Central Substance P Receptors, Science, 281 1640
66. Swain C J, (1998) Neurokinin Receptor Antagonists, Progress in Medicinal Chemistry 35, 57
67. Harper S, Bilsand J, Young L, Bristow L, Boyce S, Mason G, Rigby M, Hewson L, Smith D,
O’Donnell R, O’conner D, Hill R G, Evans D, Swain C, Williams B, Hefti F. (1998) Analysis of
the neurotrophic effects of GPI-1046 on neuronal survival and regeneration in culture and in
vivo, Neuroscience 88, 1, 257
68. Smith A L, Stevenson G I, Swain C J, Castro J L, (1998) Traceless Solid Phase Synthesis of 2,3-
Disubstituted Indoles, Tet. Lett., 39 8317.
69. Booth S E, Jenkins P R, Swain C J, (1998) The preparation and Intramolecular Radical
Cyclisation Reactions of oxime ethers, J. Braz. Chem. Soc. 9, 4, 389.
70. Stevenson, G I.; Huscroft, I; MacLeod, A M.; Swain, C J.; Cascieri, M A.; Chicchi, G G.;
Graham, M I.; Harrison, T; Kelleher, F J.; Kurtz, M; Ladduwahetty, T; Merchant, K J.; Metzger,
J M.; MacIntyre, D. E.; Sadowski, S; Sohal, B; Owens, A P. (1998) 4,4-Disubstituted Piperidine
High-Affinity NK1 Antagonists: Structure-Activity Relationships and in Vivo Activity, J. Med.
Chem, 41, 23, 4623.
71. Harrison, T. Korsgaard, M. P. G.; Swain, C. J. Cascieri, M. A. Sadowski, S. Seabrook, G. R
(1998) High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a
common structural template, Bioorg. Med. Chem. Lett. 8, 11, 1343
72. Swain C J, Harper S, Pollack S, Smith R, Hefti F. (1998) Neurotrophic Factor Mimetics, Rev.
Exp Pharm. 134, 281
73. Harper, S.; Bilsland, J.; Young, L.; Bristow, L.; Boyce, S.; Mason, G.; Rigby, M.; Hewson, L.;
Smith, D.; O’Donnell, R.; O’Connor, D.; Hill, R. G.; Evans, D.; Swain, C.; Williams, B.; Hefti, F.
(1998), Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in
culture and in vivo. Neuroscience 88(1), 257-267.
74. Hollingworth, G J.; Dinnell, K; Dickinson, L C.; Elliott, J M.; Kulagowski, J J.; Swain, C J.;
Thomson, C G. (1999), A convenient method for the preparation of aryl cyclopropyl ethers from
phenols. Tetrahedron Lett. 40(13), 2633-2636.
75. Seward, E. M.; Swain, C J. (1999) Neurokinin receptor antagonists. Expert Opin. Ther. Pat.
9(5), 571-582.
76. Swain C J, Rupniak N M J. (1999) Recent developments in Neurokinin Antagonists Annual
Reports in Medicinal Chemistry
77. Harper S J; Saporito M S; Hewson L; Young L; Smith D; Rigby M; Jackson P; Curtis N; Swain
C; Hefti F; Vaught J L; Sirinathsinghji D (2000) CEP-1347 increases ChAT activity in culture
and promotes cholinergic neurone survival following fimbria-fornix lesion. Neuroreport, 11(10),
2271-6.
78. Kulagowski J J; Curtis N R; Swain C J; Williams B J. (2001) Stereocontrolled syntheses of
epimeric 3-aryl-6-phenyl-1-oxa-7-azaspiro(4.5)decane NK-1 receptor antagonist precursors.
Organic Letters, 3(5), 667-70.
79. Cooper L C; Chicchi G G; Dinnell K; Elliott J M; Hollingworth G J; Kurtz M M; Locker K L;
Morrison D; Shaw D E; Tsao K L; Watt A P; Williams A R; Swain C J (2001) 2-Aryl indole
NK1 receptor antagonists: optimisation of indole substitution. Bioorganic and Medicinal
Chemistry Letters, 11(9), 1233-6.
80. Dinnell K; Chicchi G G; Dhar M J; Elliott J M; Hollingworth G J; Kurtz M M; Ridgill M P;
Rycroft W; Tsao K L; Williams A R; Swain C J. (2001) 2-Aryl indole NK1 receptor antagonists:
optimisation of the 2-aryl ring and the indole nitrogen substituent. Bioorganic and Medincinal
Chemistry Letters, 11(9), 1237-40
81. Shaw D; Chicchi G G; Elliott J M; Kurtz M; Morrison D; Ridgill M P; Szeto N; Watt A P;
Williams A R; Swain C J (2001) 2-Aryl indole NK(1) antagonists: optimisation of the amide
substituent Bioorganic and Medicinal Chemistry Letters, 11(23), 3031-4.
82. Harrison T; Owens A P; Williams B J; Swain C J; Williams A; Carlson E J; Rycroft W; Tattersall
F D; Cascieri M A; Chicchi G G; Sadowski S; Rupniak N M; Hargreaves R J. (2001) An orally
active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral
clinical administration. Journal of Medicinal Chemistry, 44(24), 4296-9
83. Maubach K A; Martin K; Chicchi G; Harrison T; Wheeldon A; Swain C J; Cumberbatch M J;
Rupniak N M J; Seabrook G R. (2002) Chronic substance P (NK1) receptor antagonist and
conventional antidepressant treatment increases burst firing of monoamine neurones in the locus
coeruleus. Neuroscience, 109(3), 609-17.
84. Elliott J M; Castro J L; Chicchi G G; Cooper L C; Dinnell K; Hollingworth G J; Ridgill M P;
Rycroft W; Kurtz M M; Shaw D E; Swain C J; Tsao K-L; Yang L. (2002) 4,4-Disubstituted
cyclohexylamine NK(1) receptor antagonists I. Bioorganic and Medicinal Chemistry Letters.
12(13), 1755-8
85. Cooper L C; Carlson E J; Castro J L; Chicchi G G; Dinnell K; Di Salvo J; Elliott J M;
Hollingworth G J; Kurtz M M; Ridgill M P; Rycroft W; Tsao K-L; Swain C J. (2002) 4,4-
Disubstituted cyclohexylamine NK(1) receptor antagonists II. (2002) Bioorganic and
Medicinnal Chemistry Letters, 12(13), 1759-62
86. Seward E M; Carlson E; Harrison T; Haworth K R; Herbert R; Kelleher F J; Kurtz M M; Moseley
J; Owen S N; Owens A P; Sadowski S J; Swain C J; Williams B J. (2002) Spirocyclic NK(1)
antagonists I: [4.5] and [5.5]-spiroketals. Bioorganic and Medicinal chemistry Letters. 12(18),
2515-8
87. Conley R K; Cumberbatch M J; Mason G S; Williamson D J; Harrison T; Locker K; Swain C;
Maubach K; O’Donnell R; Rigby M; Hewson L; Smith D; Rupniak N M J. (2002) Substance P
(neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. Journal of
Neuroscience. 22(17), 7730-6.
88. Williams B J; Cascieri M A; Chicchi G G; Harrison T; Owens A P; Owen S N; Rupniak N M J;
Tattersall D F; Williams A; Swain C J (2002) Spirocyclic NK(1) antagonists II: [4.5]-spiroethers.
Bioorganic and Medicinal Chemistry Letters, 12(19), 2719-22.
89. Swain, C. (2003) NK1 receptor antagonists. (2002) Editor(s): King, Frank D. Medicinal
Chemistry (2nd Edition), 415-427. Publisher: Royal Society of Chemistry, Cambridge.
90. Rupniak, N M. J.; Carlson, E J.; Shepheard, S; Bentley, G; Williams, A R.; Hill, A; Swain, C;
Mills, S G.; Di Salvo, J; Kilburn, R; Cascieri, M A.; Kurtz, M M.; Tsao, K-L; Gould, S L.;
Chicchi, G G. (2003) Comparison of the functional blockade of rat substance P (NK1) receptors
by GR205171, RP67580, SR140333 and NKP-608., Neuropharmacology 45(2), 231-241.
91. Raubo, P; Kulagowski, J J.; Swain, C J. (2003) A stereoselective synthesis of (
phenyl-1-oxa-7-azaspiro[4.5]-decanes. Synlett (13), 2021-2024.
92. Thomson CG, Carlson E, Chicchi GG, Kulagowski JJ, Kurtz MM, Swain CJ, Tsao KL, Wheeldon A. (2006) Synthesis and structure-activity relationships of 8-azabicyclo[3.2.1]octane benzylamine NK1 antagonist, Bioorg Med Chem Lett. 15;16(4), 811-4 .
93. Gregory J. Hollingworth, , Emma J. Carlson, José L. Castro, Gary G. Chicchi, Natalie Clark,
Laura C. Cooper, Olivier Dirat, Jerry Di Salvo, Jason M. Elliott, Ruth Kilburn, Marc M. Kurtz,
Wayne Rycroft, F. David Tattersall, Kwei-Lan Tsao and Christopher J. Swain. (2006) Novel
lactam NK1 antagonists with anti-emetic activity. Biorg and Medchem Lett 16, 1197
94. Swain C. J., iBabel, CDK News, vol. 3, issue 1, pages 19-20
95. Christopher J. Swain, Ana Teran, Marta Maroto and Angeles Cabello (2006)
Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands. Biorg and Medchem Lett 16, 6058.
96. Swain C: Open access and medicinal chemistry. Chem Cent J; 2007;1:2
97. Swain C J, Big Pharma in Crisis. European Pharmaceutical Contractor June 2012 12-16
98. Dr E. Zartler, Dr C. Swain & S. Pearce. Fragment library design: the evolution of fragment-based lead discovery Drug Discovery World, Winter 2012/13
99. P. Patrizia Mangione, Stéphanie Deroo, Stephan Ellmerich, Vittorio Bellotti, Simon Kolstoe, Stephen P. Wood, Carol V. Robinson, Martin D. Smith, Glenys A. Tennent, Robert J. Broadbridge, Claire E. Council, Joanne R. Thurston, Victoria A. Steadman, Antonio K. Vong, Christopher J. Swain, Mark B. Pepys, Graham W. Taylor Bifunctional crosslinking ligands for transthyretin. Open Biol. 2015 Sep;5(9):150105. doi: 10.1098/rsob.150105.
100. C. J. Swain, Data Analysis and Visualization Tools, Reference Module in Chemistry, Molecular Sciences and Chemical Engineering, 2016, ISBN 978-0-12-409547-2
101. Alice E. Williamson, Paul M. Ylioja, Murray N. Robertson, Yevgeniya Antonova-Koch, Vicky Avery, Jonathan B. Baell, Harikrishna Batchu, Sanjay Batra, Jeremy N. Burrows, Soumya Bhattacharyya, Felix Calderon, Susan A. Charman, Julie Clark, Benigno Crespo, Matin Dean, Stefan L. Debbertγ, Michael Delves, Adelaide S. M. Dennis, Frederik Deroose, Sandra Duffy, Sabine Fletcher, Guri Giaever, Irene Hallyburton, Francisco-Javier Gamo, Marinella Gebbia, R. Kiplin Guy, Zoe Hungerford, Kiaran Kirk, Maria J. Lafuente-Monasterio, Anna Leeη, Stephan Meister, Corey Nislow, John P. Overington, George Papadatos, Luc Patiny, James Pham, Stuart A. Ralph, Andrea Ruecker, Eileen Ryan, Christopher Southan, Kumkum Srivastava, Chris Swain, Matthew J. Tarnowski, Patrick Thomson, Peter Turner, Iain M. Wallace, Timothy N. C. Wells, Karen White, Laura White, Paul Willis, Elizabeth A. Winzeler, Sergio Wittlin, and Matthew H. Todd, Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles, ACS Cent. Sci., 2016, 2 (10), pp 687–701
102. Jan H. Jensen , Christopher J. Swain, and Lars Olsen, Prediction of pKa Values for Druglike Molecules Using Semiempirical Quantum Chemical Methods, J. Phys. Chem. A, 2017, 121 (3), pp 699–707
103. Brian Cox, James Duffy, Victor Zdorichenko, Corentin Bellanger, Jessica Hurcum, Benoît Laleu, Kevin I. Booker-Milburn, Luke D. Elliott, Michael Robertson-Ralph, Christopher J. Swain, Stephen J. Bishop, Irene Hallyburton, and Mark Anderson ACS Med. Chem. Lett. 2020, 11, 12, 2497–2503.
104. Iain W. McNae, James Kinkead, Divya Malik, Li-Hsuan Yen, Martin K. Walker, Chris Swain, Scott P. Webster, Nick Gray, Peter M. Fernandes, Elmarie Myburgh, Elizabeth A. Blackburn, Ryan Ritchie, Carol Austin, Martin A. Wear, Adrian J. Highton, Andrew J. Keats, Antonio Vong, Jacqueline Dornan, Jeremy C. Mottram, Paul A. M. Michels, Simon Pettit & Malcolm D. Walkinshaw, Fast acting allosteric phosphofructokinase inhibitors block trypanosome glycolysis and cure acute African trypanosomiasis in mice. Nat Commun 12, 1052 (2021).
105. Bethanie A. Clent, Yuhang Wang, Hugh C. Britton, Frank Otto, Christopher J. Swain, Matthew H. Todd, Jonathan D. Wilden, and Alethea B. Tabor. Molecular Docking with Open Access Software: Development of an Online Laboratory Handbook and Remote Workflow for Chemistry and Pharmacy Master’s Students to Undertake Computer-Aided Drug Design. J. Chem. Educ. 2021, 98, 9, 2899–2905
106 Dana M. Klug, Edwin G. Tse, Daniel G. Silva, Yafeng Cao, Susan A. Charman, Jyoti Chauhan, Elly Crighton, Maria Dichiara, Chris Drake, David Drewry, Flavio da Silva Emery, Lori Ferrins, Lee Graves, Emily Hopkins, Thomas A. C. Kresina, Álvaro Lorente-Macías, Benjamin Perry, Richard Phipps, Bruno Quiroga, Antonio Quotadamo, Giada N. Sabatino, Anthony Sama, Andreas Schätzlein, Quillon J. Simpson, Jonathan Steele, Julia Shanu-Wilson, Peter Sjö, Paul Stapleton, Christopher J. Swain, Alexandra Vaideanu, Huanxu Xie, William Zuercher, and Matthew H. Todd Open Source Antibiotics: Simple Diarylimidazoles Are Potent against Methicillin-Resistant Staphylococcus aureus ACS Infectious Diseases 2023, 9, 12, 2423-2435
107 P. Patrizia Mangione, Guglielmo Verona, Cristina Cantarutti, Paola Nocerino, Maria Chiara Mimmi, Christopher J. Swain, Diana Canetti, Sofia Giorgetti, Iain Uings, Julian D. Gillmore, Graham W. Taylor, Mark B. Pepys, Vittorio Bellotti, Alessandra Corazza Design and Mechanistic Analysis of a Potent Bivalent Inhibitor of Transthyretin Amyloid Fibrillogenesis Journal of Medicinal Chemistry 2025 Vol 68/Issue 11 11543.
108. Mia Urem, Annemieke H. Friggen, Nina Musch, Michael H. Silverman, Christopher J. Swain, Michael R. Barbachyn, Lawrence I. Mortin, Xiang Yu, Robert J. DeLuccia, Meindert H. Lamers & Wiep Klaas Smits. A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens. Nat Commun 16, 9784 (2025). https://doi.org/10.1038/s41467-025-65324-8